RETATRUTIDE PEN

OVERVIEW

Retatrutide is a triple agonist peptide (targeting GLP-1, GIP, and glucagon receptors) currently in clinical development for weight management and type 2 diabetes, with no FDA-approved commercial pens available in the US as of May 2026. 

• Availability: Official Eli Lilly retatrutide is not yet approved for general sale; products labeled as “Retatrutide Pens” on various websites are typically unapproved, export-only, or research-grade peptides (e.g., Salkalli, ZPHC) with uncertain safety and legality for US consumers. 

• Dosage & Administration: Clinical trials utilized a weekly subcutaneous injection with a titration schedule starting at 2.5 mg and increasing to a maintenance dose of 10 mg (or higher in later trials).  Some unapproved 30mg pens are marketed as having 300 clicks (0.1 mg per click).

• Injection Method: Approved GLP-1 analogs like Wegovy use pre-filled disposable pens; users seeking retatrutide often use reusable insulin pens (e.g., Lilly Ergo, Savvio) with refillable cartridges, though this involves compounding risks. 

• Warnings: Common side effects include nausea, vomiting, and diarrhea.  Serious risks involve pancreatitis, gallbladder disease, and hypoglycemia.  Use is contraindicated in pregnancy, breastfeeding, and those with a history of severe hypoglycemia.